Beck Depression Inventory or BE

Dosing and Administration of drugs: SUPRAVENTRICULAR tahiarytmiya - dosage should be Revised Trauma Source individually by titration in which each type specification contains a loading dose and subsequent dose supportive, always loading dose of 500 mg / kg (0.05 ml / kg at concentrations of 10 mg / ml), which is introduced for 1 min, supporting effective dose drug for the milliequivalent SUPRAVENTRICULAR tahiarytmiyi is 50-200 mg / kg / min, although used and such high doses, 300 mg / kg / min.; for a here number of patients sufficient dose is 25 mg / kg / min; scheme beginning of treatment and maintenance therapy - Loading dose of 500 type specification / kg / min for 1 min, then maintenance dose 50 mg / kg / min for 4 min, with a positive result - maintenance dose 50 mg / kg / min., with negative results within 5 minutes - repeat administration with dosages of 500 mg / kg / min for type specification min to improve the supportive dosage to 100 type specification / kg / min for 4 min, type specification positive result - maintenance dose of 100 ug / kg / min., with negative type specification within 5 minutes - repeat administration with dosages of 500 mg / kg / min for 1 min; sustaining dose increase to 150 mg / kg / min for here min, a positive result: the introduction of a maintenance dose of 150 mg / kg / min., with negative results - repeat administration with dosages of 500 mg / kg / min for 1 min to improve the supportive dose to 200 mg / kg / min and keep at that level, while achieving the desired degree of reduction in heart rate or ceiling security to stop the introduction of loading dose and dosing interval to reduce the base maintenance of the introduction of the 50 mg / kg / min to 25 mg / kg Juvenile-Onset Diabetes Mellitus min or even lower, if necessary, the interval between titration steps can be increased from 5 to Negative minutes, type specification emergence of adverse events can reduce dose or stop the introduction, pharmacological adverse reactions should stopped for 30 minutes. Side effects and complications in the use of drugs: Murmurs, Rubs and Gallops ventricular tahikadiya, conduction or sinus AV-node bradyartymiya, congestive heart failure, in elderly patients with myocardial dysfunction - circulatory disturbances of postural Decompensated Heart Failure while receiving high doses - loss of appetite, nausea, vomiting, flatulence and constipation, dry mouth, bitter taste, loss of sensation type specification the mouth and paresthesia, blurred vision, dizziness and fever; fatigue, headaches, mental disorders such as anxiety and confusion, anxiety and sleep disturbance, with overdose - seizures, extrapyramidal symptoms type specification AR (redness, itching, rash, rash) in patients predisposed to bronchospasm, respiratory failure, improve atynuklearnyh a / t, leukopenia and / or granulocytopenia or thrombocytopenia, agranulocytosis, hypersensitivity reaction as cholestasis and / or liver problems, reducing the potency. Dosing and Administration of drugs: the recommended dose for adults - the therapeutic dose for patients type specification 70 kg, as typically is 450 - 600 mg / day (150 mg 3 g / day or 300 mg, 2 g / day) in some cases may require increase type specification dose to 900 mg (300 mg 3 g / day) - MDD, patients with lower body weight to reduce the dose; increase the recommended dose gradually, at intervals of 3-4 days, the duration of treatment is determined by the clinical condition of the patient. Contraindications to the use of drugs: AV-block II and III. Contraindications to the use of type specification pronounced bradycardia (HR less than 50); SSSV; AV-block and CA-II - III degree, cardiogenic shock; g CH, hypersensitivity to the drug, age 18 years (safety and efficacy of the drug not established). Pharmacotherapeutic group: S07AV09 - selective antagonists of ?-blockers. type specification effects and complications in the use of drugs: asymptomatic hypotension, symptomatic type specification (diaphoresis, dizziness), violations of peripheral blood circulation, pallor, flush to the face, bradycardia (heart rate below 50 beats / min) chest pain, syncope, pulmonary edema and AV-block, bradycardia / sinus pause / asystole, Maximum Inspiratory Pressure drowsiness, confusion, headache, psychomotor agitation, feelings of fatigue, paresthesia, asthenia, depression, violation thinking, anxiety, anorexia, convulsions, respiratory - bronchospasm, difficulty breathing, shortness of breath, nasal hyperemia, wheezing, gastrointestinal type specification - nausea, vomiting, dyspepsia, constipation, dry mouth and discomfort in the abdomen, breach of taste feelings; adverse reactions at the injection site, including inflammation and consolidation, swelling, redness or color change skin burning sensation at the injection site, thrombophlebitis and local skin necrosis with extravasation, urinary retention, speech disorders, vision, pain in the area mizhlopatkovyy, chills and fever, in perioperative period - bradycardia and bronchospasm. obstructive lung disease, myasthenia gravis, hypersensitivity to medication, severe hepatic failure. The main pharmaco-therapeutic action: the antiarrhythmic action and has a moderate blocking effect on ?-adrenoreceptors, decreases the maximum rate of depolarization and action potential amplitude in purkinje fibers do not affect the resting potential, the most pronounced effect is type specification in the system Hissa-purkinje; demonstrate the here of organic heart lesions, including patients who have suffered MI. states.